Vasogenix Pharmaceuticals

VasoGenix Video Coming Soon.
Please check back soon.

VasoGenix Pharmaceuticals, Inc. is developing intravenous and controlled release drug (CRD) treatments for addressing Heart Failure and other cardiac diseases in order to reduce the recurrence of these diseases and their resulting hospital and medical costs.

At VasoGenix we are not satisfied just treating the symptoms of heart failure. Our goal is to slow the progression, decrease hospital stays and readmissions. To do so requires a special drug with unique with properties. It requires the perfect drug for the heart.

Company Information (PPT)
About VasoGenix

VasoGenix Video (12 minutes)

Recent News

05/19/2009
VasoGenix Pharmaceuticals elects Cleveland Clinic’s James Young, M.D., to its board of directors
LENEXA, Kan., May 19, 2009—VasoGenix Pharmaceuticals announced today that heart failure/heart transplant cardiologist James Young, M.D., has been elected to its board of directors.
03/23/2009
VasoGenix Pharmaceuticals Elects Pharma Industry Veteran Dr. Judith A. Hemberger to Its Board of Dir
LENEXA, Kan.--(BUSINESS WIRE)-- VasoGenix Pharmaceuticals announced today that Judith A. Hemberger, Ph.D., has been elected to its board of directors. Dr. Hemberger is currently a director of Zymogenetics, Chroma, Atani Ltd., and Zosano Pharma.
02/11/2009
VasoGenix Selects a Lead CGRP Agonist Analog to Develop as a Heart Failure Treatment
LENEXA, Kan., Feb 11, 2009 (BUSINESS WIRE) -- VasoGenix Pharmaceuticals Inc. (www.vasogenix.net) announced today that initial in vitro screening of a series of synthetic agonist analogs of calcitonin gene-related peptide (CGRP) exhibit similar receptor site binding properties as CGRP.